Compare EHAB & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EHAB | LENZ |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 692.9M | 609.5M |
| IPO Year | 2020 | 2021 |
| Metric | EHAB | LENZ |
|---|---|---|
| Price | $13.97 | $9.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $13.84 | ★ $45.60 |
| AVG Volume (30 Days) | 1.0M | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.11 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,060,000,000.00 | $19,088,000.00 |
| Revenue This Year | $6.42 | $51.35 |
| Revenue Next Year | $4.88 | $198.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.44 | N/A |
| 52 Week Low | $6.47 | $8.25 |
| 52 Week High | $14.22 | $50.19 |
| Indicator | EHAB | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 73.78 | 43.33 |
| Support Level | $10.79 | $8.25 |
| Resistance Level | $14.22 | $12.70 |
| Average True Range (ATR) | 0.09 | 0.76 |
| MACD | -0.06 | 0.17 |
| Stochastic Oscillator | 57.50 | 66.67 |
Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services for adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing a life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.